{"id":69145,"date":"2026-07-01T11:55:33","date_gmt":"2026-07-01T03:55:33","guid":{"rendered":"https:\/\/flcube.com\/?p=69145"},"modified":"2026-07-01T11:55:34","modified_gmt":"2026-07-01T03:55:34","slug":"beone-medicines-reports-43-reduction-in-disease-progression-with-brukinsa-rituximab-combo-in-phase-iii-mcl-study-chemotherapy-free-regimen-shows-significant-pfs-benefit","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69145","title":{"rendered":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced today <strong>positive top-line results<\/strong> from the <strong>Phase III MANGROVE study<\/strong> (BGB-3111-306; NCT04002297) evaluating <strong>BRUKINSA\u00ae (zanubrutinib capsules)<\/strong> in combination with <strong>rituximab<\/strong> versus <strong>bendamustine plus rituximab (BR)<\/strong> as first-line treatment for <strong>previously untreated Mantle Cell Lymphoma (MCL)<\/strong> in adult patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trial met its primary endpoint with the <strong>BRUKINSA-based chemotherapy-free regimen<\/strong> demonstrating a <strong>43% reduction in the risk of disease progression or death<\/strong> (HR=0.57; [95% CI, 0.43, 0.76]; p&lt;0.0001), establishing a new potential standard of care for this aggressive B-cell malignancy.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-summary\" class=\"wp-block-heading\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>BRUKINSA + Rituximab<\/th><th>Bendamustine + Rituximab<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Progression-Free Survival (PFS)<\/strong><\/td><td>HR=0.57 (95% CI: 0.43\u20130.76)<\/td><td>Reference<\/td><td><strong>43% risk reduction<\/strong> (p&lt;0.0001)<\/td><\/tr><tr><td><strong>Secondary: Overall Survival (OS)<\/strong><\/td><td>Trend favoring BRUKINSA combo<\/td><td>Not mature at analysis<\/td><td>Final OS analysis pending<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with known profiles<\/td><td>Standard chemotherapy toxicity<\/td><td><strong>No new safety signals<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-brukinsa-zanubrutinib\" class=\"wp-block-heading\">BRUKINSA (Zanubrutinib)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Oral small-molecule <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Design Rationale:<\/strong> Engineered for <strong>complete and sustained BTK inhibition<\/strong> through optimized:<\/li>\n\n\n\n<li><strong>Bioavailability:<\/strong> Enhanced absorption and exposure<\/li>\n\n\n\n<li><strong>Half-life:<\/strong> Extended duration of action enabling consistent target coverage<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Reduced off-target effects compared to earlier-generation BTK inhibitors<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Exhibits <strong>superior pharmacokinetic characteristics<\/strong> compared to other approved BTK inhibitors, potentially translating to improved efficacy and tolerability<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-treatment-paradigm-shift\" class=\"wp-block-heading\">Treatment Paradigm Shift<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chemotherapy-Free Approach:<\/strong> Represents a significant advancement over traditional cytotoxic regimens<\/li>\n\n\n\n<li><strong>Targeted Therapy:<\/strong> Leverages precision medicine principles to specifically inhibit B-cell receptor signaling<\/li>\n\n\n\n<li><strong>Patient Benefits:<\/strong> Potential for reduced acute toxicity, improved quality of life, and outpatient administration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-competitive-landscape\" class=\"wp-block-heading\">Market Implications &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mantle Cell Lymphoma Market:<\/strong> Estimated global market size of <strong>USD 1.2 billion by 2028<\/strong>, with limited first-line treatment options<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> BRUKINSA becomes the <strong>first BTK inhibitor to demonstrate superiority over standard chemoimmunotherapy<\/strong> in untreated MCL<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Results support potential <strong>label expansion<\/strong> for first-line MCL indication across major markets (US FDA, EMA, NMPA)<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Addresses significant unmet need in frontline setting where current standard involves intensive chemotherapy with substantial toxicity burden<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-beone-medicines\" class=\"wp-block-heading\">Strategic Significance for BeOne Medicines<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Strengthens BRUKINSA&#8217;s position beyond current indications (WM, CLL\/SLL, MZL)<\/li>\n\n\n\n<li><strong>Global Commercial Impact:<\/strong> Positive data expected to drive adoption across BeOne&#8217;s established commercial infrastructure in US, China, and EU<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Reinforces company&#8217;s expertise in hematologic malignancies and targeted therapy development<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> First-line MCL indication could add <strong>USD 300\u2013500 million<\/strong> in peak annual revenue based on market sizing and pricing assumptions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations. Actual outcomes may differ due to risks including final regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688235_20260701_7SWS.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688235_20260701_7SWS.\"><\/object><a id=\"wp-block-file--media-4b95e6e0-f331-4699-b808-e4c88468e8e5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688235_20260701_7SWS.pdf\">688235_20260701_7SWS<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688235_20260701_7SWS.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4b95e6e0-f331-4699-b808-e4c88468e8e5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69146,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2092,16,17,847,3046,848,33],"class_list":["post-69145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beone-medicines","tag-cancer","tag-clinical-trial-results","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69145\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69145\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-01T03:55:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-01T03:55:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit\",\"datePublished\":\"2026-07-01T03:55:33+00:00\",\"dateModified\":\"2026-07-01T03:55:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0101.webp\",\"keywords\":[\"BeOne Medicines\",\"Cancer\",\"Clinical trial results\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69145#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69145\",\"name\":\"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0101.webp\",\"datePublished\":\"2026-07-01T03:55:33+00:00\",\"dateModified\":\"2026-07-01T03:55:34+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69145\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0101.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69145#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69145","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.","og_url":"https:\/\/flcube.com\/?p=69145","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-01T03:55:33+00:00","article_modified_time":"2026-07-01T03:55:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69145#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69145"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit","datePublished":"2026-07-01T03:55:33+00:00","dateModified":"2026-07-01T03:55:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69145"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","keywords":["BeOne Medicines","Cancer","Clinical trial results","HKG: 6160","NASDAQ: ONC","SHA: 688235","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69145#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69145","url":"https:\/\/flcube.com\/?p=69145","name":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69145#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","datePublished":"2026-07-01T03:55:33+00:00","dateModified":"2026-07-01T03:55:34+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from the Phase III MANGROVE study (BGB-3111-306; NCT04002297) evaluating BRUKINSA\u00ae (zanubrutinib capsules) in combination with rituximab versus bendamustine plus rituximab (BR) as first-line treatment for previously untreated Mantle Cell Lymphoma (MCL) in adult patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69145#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69145"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69145#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","width":1080,"height":608,"caption":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69145#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study \u2013 Chemotherapy-Free Regimen Shows Significant PFS Benefit"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69145"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69145\/revisions"}],"predecessor-version":[{"id":69148,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69145\/revisions\/69148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69146"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}